Non-viral delivery

Non-viral delivery for gene therapy A next generation gene therapy delivery approach The Duchenne Research Fund has committed £640,000 to accelerate research into alternative ways to deliver gene therapy to Duchenne patients, with the aim of increasing the number of...

CRISPR

CRISPR for Duchenne Genome editing technology to correct the mutated dystrophin gene The Duchenne Research Fund has awarded a £200,000 grant to the team at the Hospital for Sick Children in Toronto, Canada (‘Sick Kids’), who are working on using...

Gene therapy for Becker

Gene therapy for Becker A microdystrophin gene therapy approach for Becker muscular dystrophy We have awarded a grant to the team of Professor Thomas Voit (pictured) at the Great Ormond Street Biomedical Research Centre at UCL to develop a microdystrophin gene therapy...

Activity monitoring biomarker – KineDMD

KINEDMD study: developing an activity monitoring biomarker Using novel algorithms to chart daily activities of ambulant and non-ambulant boys The KineDMD study overseen by Imperial College London is now open for recruitment. The study will recruit 16 Duchenne muscular...

Blood-based biomarker

Blood-based biomarker Developing a more informative measure of disease progression and response to new treatments Although Duchenne has been studied for many years, classic measures of disease progression rely on basic observations of movement, such as the six-minute...